KH-CB19
Based on 1 publication(s) in Google Scholar
KH-CB19 is a potent CLK (cdc2-like kinase) inhibitor (CLK1 IC50=19.7 nM; CLK3 IC50=530 nM). KH-CB19 shows antiviral activity and inhibits influenza virus replication (IC50=13.6?μM).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.09%
- CAS No.: 1354037-26-5
- 화학식: C15H13Cl2N3O2
- 분자량:338.19
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) KH-CB19
More
Biological Activity
|
CLK1 19.7 nM (IC50) |
CLK3 530 nM (IC50) |
DYRK1A 55.2 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-22 | IC50 |
>100 μM
Compound: 17; KH-CB19
|
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 36876904] |
KH-CB19 (10 μM; 1 h) shows CLK inhibition on SR protein phosphorylation in human microvascular endothelial cells[1].
KH-CB19 (50?μM; 6 h) inhibits the disruption by CLK4 in A549?cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human microvascular endothelial cells (HMEC-1)
-
Concentration:10 μM
-
Incubation Time:1 hour
-
Result:Led to a reduced phosphorylation of SRp75, SRp55, and SRp20 compared with non TNF-α-stimulated controls.
Led to a reduction of the TNF-α-induced increase in phosphorylation of all analyzed SR proteins compared with TNF-α-stimulated controls.
Chemical Information
-
CAS No. 1354037-26-5
-
Appearance Solid
-
분자량 338.19
-
화학식 C15H13Cl2N3O2
-
Color White to light yellow
-
SMILES
CCOC(C1=C(C2=C(C(Cl)=C(C=C2)Cl)N1C)/C(C#N)=C\N)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175
용액&용해도
DMSO : ≥ 50 mg/mL (147.85 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9569 mL | 14.7846 mL | 29.5692 mL | 73.9229 mL |
| 5 mM | 0.5914 mL | 2.9569 mL | 5.9138 mL | 14.7846 mL | |
| 10 mM | 0.2957 mL | 1.4785 mL | 2.9569 mL | 7.3923 mL | |
| 15 mM | 0.1971 mL | 0.9856 mL | 1.9713 mL | 4.9282 mL | |
| 20 mM | 0.1478 mL | 0.7392 mL | 1.4785 mL | 3.6961 mL | |
| 25 mM | 0.1183 mL | 0.5914 mL | 1.1828 mL | 2.9569 mL | |
| 30 mM | 0.0986 mL | 0.4928 mL | 0.9856 mL | 2.4641 mL | |
| 40 mM | 0.0739 mL | 0.3696 mL | 0.7392 mL | 1.8481 mL | |
| 50 mM | 0.0591 mL | 0.2957 mL | 0.5914 mL | 1.4785 mL | |
| 60 mM | 0.0493 mL | 0.2464 mL | 0.4928 mL | 1.2320 mL | |
| 80 mM | 0.0370 mL | 0.1848 mL | 0.3696 mL | 0.9240 mL | |
| 100 mM | 0.0296 mL | 0.1478 mL | 0.2957 mL | 0.7392 mL |
KH-CB19 Related Classifications
HY-12828 Related Classifications
Powered by Bioz